Sign In
Free Newsletter
On the scene: New Jersey Innovation Hub launches at HELIX
NJBIZ was on the scene July 14 as BioNJ officially signed on as a foundational member of the New Jersey Innovation Hub, Powered by Portal.
Portal opens NJ Innovation Hub at HELIX with 16 startups
Portal Innovations has opened the NJ Innovation Hub at HELIX in New Brunswick with 16 founding startups and life sciences support.
Novartis cutting 322 more jobs at NJ headquarters (updated)
Novartis will cut 322 jobs at its East Hanover headquarters, marking the fourth round of New Jersey layoffs this year.
Novartis to acquire Myricx Bio in $1.5B cancer deal
Novartis will acquire Myricx Bio for up to $1.5B, expanding its antibody-drug conjugate pipeline for cancer treatments.
Merck tops New Jersey life sciences employers list
Merck leads New Jersey's largest life sciences employers, followed by NJIT, BD and Montclair State University.
New Jersey builds on legacy of leadership in life sciences
New Jersey's life sciences industry tops 127,000 workers as a new report highlights biotech growth, manufacturing and innovation.
Report: NJ expands life sciences leadership
New Jersey expands its life sciences leadership with biotech growth, new biomanufacturing space and innovation investments.
INNOVATE100 celebrates tech leaders across New Jersey
INNOVATE100 honored more than 300 New Jersey innovation leaders during a networking event in New Brunswick.
Advance bringing 1M-SF life sciences campus to Bridgewater
The Continuum project will emphasize advanced manufacturing and logistics, too, to establish an end-to-end innovation ecosystem in Somerset County featuring amenities, retail space and more.
Novartis reports progress on $23B US manufacturing expansion
Novartis advances its $23B U.S. manufacturing plan, expanding R&D and drug production as it aims to produce key medicines domestically.
Leaders preview NJ Innovation Hub at HELIX
Leaders preview the HELIX NJ Innovation Hub in New Brunswick, highlighting life sciences collaboration, startup support – and why New Brunswick is an ideal location for the facility.
Cellares to manufacture Cabaletta CAR-T under 10-year deal
The 10-year deal will enable automated, large-scale production for autoimmune diseases with Cabaletta Bio's rese-cel therapy.
